Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises & Experts

通过生态系统、企业增加 IDeA 州生物医学创业精神

• 批准号: 10761120
• 负责人: Julius N. Korley
• 金额: $ 27.36万
• 依托单位: INSITEHUB LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-21 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10761120
• 关键词: Address; Area; Award; Basic Science; Biological Models; Biomedical Research; Biotechnology; Businesses; Cessation of life; Chemistry; Critical Pathways; Data; Delaware; Development; Disclosure; Ecosystem; Education; Educational Curriculum; Engineering; Ensure; Entrepreneurship; Evaluation; Exposure to; Failure; Funding; Goals; Institution; Intervention; Interview; Knowledge; Learning; Legal patent; Licensing; Marketing; Measures; Medical; Medical Technology; Mentors; Methodology; Modeling; Monitor; National Institute of General Medical Sciences; Participant; Pathway interactions; Patients; Performance; Pharmacologic Substance; Phase; Phase Transition; Price; Private Sector; Process; Program Evaluation; Readiness; Request for Proposals; Resources; Science; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Technology; Technology Transfer; Testing; Training; Translating; Universities; Voice; Work; cohort; commercialization; experience; ideation; improved; innovation; innovative technologies; insight; invention; new technology; online course; outreach; product development; programs; prototype; research study; success; technology development; trend; validation studies

Summary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer interviews regarding challenges to the commercialization of biomedical innovations, there are 3 main barriers to translating basic science products that benefit patients, 1) gap in funding between basic research and validation studies required for early-stage development, 2) lack of knowledge and understanding by innovators about how technologies are brought to market, and 3) lack of access to sufficient technology development and commercialization resources. The creation of the IDeA state program is clear evidence of the need for resources not only to cultivate biomedical research but to spur on commercialization of the new technology created. Correctly identifying deficiencies in the commercialization pathway and preemptively providing corrective measures will create better entrepreneurs and increase the likelihood of commercialization. Our team will develop a rigorous and engaging online curriculum to support the goals and bridge the gap of sufficient training and knowledge for innovators through a high-availability, scalable, on-demand platform. The platform will help both new and experienced innovators to focus on areas of need and provide direct learning interventions from ideation, to market assessment, and go- to-market strategies and will allow for live mentoring and coaching interactions online to support and supplement the curriculum. Data and advanced insights will be analyzed for both the overall program and the learning process that will yield trends as to the correlation between innovators who are deemed successful and the parts of the program leveraged most, allowing us to continuously improve the program. This will result in a more robust education, an increase in the number of biomedical entrepreneurs, an increase in the number of biomedical startups developing market-driven technologies applying for SBIR/STTR and accessing existing ecosystem resources, and increased connectivity between innovative technologies and other enterprises and experts. The specific aims align participants and establish the DE iRED organization with deliverables that include team governance criteria and processes, and innovator roadmaps for Delaware, Northeast, and wider region/IDeA states.They also include the launch of final program and outreach campaigns (local > northeast) and programming using data obtained through pilot activities, testing the revenue model and pricing for sustainability as well as increased reach of the launch outreach campaign to the Northeast and national venue.

概括 拟议的DE IRED计划由大学和私营部门合作伙伴组成，以提供 综合计划，将在技术的早期阶段参与和支持生物医学创新者 通过在启动过程中确定的启动过程中的关键瓶颈进行商业化，并在招标和 由驱动的加速器中心。根据Driven的客户面试的声音 生物医学创新的商业化，翻译基础科学产品有3个主要障碍 受益于患者，1）早期研究所需的基础研究和验证研究之间的资金差距 开发，2）创新者缺乏有关如何将技术带入技术的知识和理解 市场，以及3）缺乏获得足够的技术开发和商业化资源的机会。 创建想法状态计划的明确证据表明，不仅需要培养生物医学的资源需要 研究，但刺激了创建的新技术的商业化。正确识别 商业化途径和先发制人提供纠正措施将创造更好的企业家 并增加商业化的可能性。我们的团队将在网上开发严格而引人入胜的 课程以支持目标并弥合创新者足够培训和知识的差距 高可用性，可扩展的按需平台。该平台将帮助新的和经验丰富的创新者 专注于需求领域，并提供直接学习干预措施，从想法到市场评估，并进行 待市场策略，并将允许在线实时心理和教练互动以支持和补充 课程。将分析整个程序和学习的数据和高级见解 流程将产生有关被认为成功的创新者与零件之间的相关性的趋势 该计划的利用最多，使我们能够继续改进该计划。这将导致更强大 教育，生物医学企业家数量的增加，生物医学数量的增加 初创企业正在申请SBIR/STTR并访问现有生态系统的市场驱动技术 资源以及创新技术与其他企业和专家之间的连通性。 具体的目的是使参与者保持一致，并建立DE IRED组织与可交付成果，包括 团队治理标准和流程，以及特拉华州，东北和怀尔德的创新路线图 地区/思想状态。其中还包括启动最终计划和外展活动（本地>东北） 并使用通过试验活动获得的数据进行编程，测试收入模型和定价 可持续性以及向东北和国家场所发射推广活动的覆盖范围增加。